CADDRA is a Canadian non-profit member association for medical and health care professionals, along with researchers, who assess, treat and/or study ADHD. | |
|
CADDRA ADHD and Substance Use Program
In January 2023, CADDRA received its first-ever federal funding from Health Canada to develop a new accredited online program!
| |
|
The CADDRA ADHD and Substance Use Program (CASUP) is aimed at improving practitioner knowledge of the assessment, diagnosis, and treatment of ADHD with co-occurring substance use (SU) or substance use disorders (SUDs).
Combining extensive research, expert input, and feedback from hundreds of stakeholders, including individuals with lived experience of ADHD and SU/SUDs, CASUP will provide multidisciplinary professional development and facilitate in-course cross-disciplinary discussion
| |
The course is expected to launch in late 2024 on CADDRA’s eLearning platform, ADHDLearn. |
| Would you like to receive advance email notification of when the course opens? | | | |
|
Highlighted Abstract
Journal articles are selected based on their clinical relevance. The commentary reflects the reviewer’s own opinion and is not approved, or necessarily representative, of the opinion of the CADDRA Board. This month’s abstract was selected by CADDRA board member, Dr. Lila Amirali.
| |
|
Treatment with psychostimulants and atomoxetine in people with psychotic disorders: Reassessing the risk of clinical deterioration in a real-world setting.
Corbeil, O., Brodeur, S., Courteau, J., Béchard, L., Huot-Lavoie, M., Angelopoulos, E., Roy, M. (2023). The British Journal of Psychiatry, 1-8. doi:10.1192/bjp.2023.149
| | |
Commentary by Dr. Lila Amirali*: Combining psychostimulants (such as methylphenidate and amphetamines) and atomoxetine with antipsychotics was associated with a decreased rate of hospital admissions for psychosis and other mental disorders compared to the previous year in a real-world study using a large health database. Individuals exposed to these medications had more complex clinical profiles than those not exposed. This aligns with a previous study on methylphenidate, indicating a protective association with psychosis. The findings challenge the perception of psychostimulant safety in schizophrenia spectrum and other psychotic disorders, suggesting that, when used in certain individuals, these medications may be safer than commonly believed. Possible explanations include improved adherence to antipsychotic medication and minimal interference of psychostimulants with the pharmacodynamics of co-prescribed antipsychotics. | |
*Lila Amirali MD, MMGMT (IMHL), FRCPC, DFAPAis a child and adolescent psychiatrist, CHU Sainte-Justine, Montreal, Quebec. | |
|
Current ADHD Research
Please note: These are links to research abstracts. Some are available without cost and others require a subscription.
| |
|
The Glenda M. MacQueen Memorial Career Development Award for Women in Psychiatry
This career development award was created to honour the accomplishments of the late Glenda MacQueen, and to support the early-stage development of women who will lead the future of academic psychiatry.
Application deadline: February 1, 2024
FIND OUT MORE
| | |
|
Brain Sciences 2024 Young Investigator Award
Brain Sciences is now accepting nominations for this prize. which will be given to one young investigator in recognition of their excellence in the field of neuroscience.
Nomination deadline: March 31, 2024
FIND OUT MORE
| |
|
Fairmont Winnipeg
Winnipeg, Manitoba
| |
|
11th Annual
ADHD Research Day
Friday, September 27
20th Annual
ADHD Conference
Saturday, September 28
& Sunday, September 29
| |
|
The CADDRA conference is the only national meeting that addresses the needs of ADHD researchers and medical and health professionals treating people with ADHD. | |
Learn more about ADHD TrEAT! | |
|
Curious about CADDRA’s ADHD Treatment Education and Assessment Tool (ADHD TrEAT) and how (or why) to integrate it into your practice?
Unsure where and how to start? Complete the free ADHD in Practice course (and earn credits while doing so).
This free member tool is used by a multidisciplinary group of members in and outside of Canada to:
- Send out assessment forms to clients with automatic reminders;
- Review graphed and detailed results;
- Send resources;
- Make referrals within a system centered on the Canadian ADHD Practice Guidelines.
A CADDRA survey completed in December by current ADHD TrEAT users found:
- Sixty-five percent found the tool very or extremely useful to their practice, 24% found it moderately useful, 10% found it slightly useful, and just 1% didn’t find it useful at all.
- Fifty-seven percent said it extremely or very much improved the efficiency of their assessment process (i.e. reduced amount of time, effort and/or resources), 31% found it moderately improved efficiency, 6% slightly and 6% not at all.
- Over half (55%) of the users found that ADHD TrEAT extremely or very much streamlined their assessment process (i.e. by making it simpler or more straightforward) by reducing steps or administrative work, 28% found a moderate improvement, 7% a slight improvement while 10% found no change.
- Eighty-nine percent of members currently using the tool intend to continue using it, 10% were unsure and only 1% did not plan to continue with its use.
| |
|
CADDRA Advocacy Committee Chair Dr. Joan Flood and CADDRA staff (Niamh McGarry and Stacey Espinet), along with Juanita Beaudry of CADDAC, presented the White Paper to departmental staff during recent meetings with:
- Office of Ontario’s Deputy Premier and Minister of Health
- Office of the Associate Minister of Mental Health & Addictions, Ontario
| |
Foquest is now listed on the PEI Formulary | |
|
Effective December 18, 2023, Foquest is listed on the PEI Formulary (special authorization) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Learn more about the eligibility criteria for reimbursement of Foquest in PEI.
| |
Visit our booth at the following events: | |
|
|
Are You Professionally Involved with ADHD?
Discover the benefits of becoming a member of CADDRA.
FIND OUT MORE
| | | | | | |
